16
Aug
30 million lives now covered by one of the largest national PBMs Continue to work with this PBM to access an additional 20 million lives The team continues to work with the national PBM’s...
Press Release
test
07
Jul
Ancora Medical Inc. (“Ancora”) is a privately held medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set which is indicated for surgical pain management during...
05
Jul
PALO ALTO, CA. July 5, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused...
14
Jun
Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults.Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As gout cases increase...
03
Jun
PALO ALTO and SAN DIEGO, CA. June 3, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial...
02
Jun
Earlier this year, a national pharmacy benefit manager (PBM) moved a large percentage of its patients from not covered to covered, adding access to ZTlido for 5.5 million lives. ZTlido is now...
18
May
Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 in subjects with moderate to severe acute lower...
16
May
PALO ALTO, CA. and NEW YORK, NY. May 16, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE,...
11
May
SP-104 is a novel, proprietary, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, for treatment of fibromyalgia (FM).There is a clear medical need for new, safe and effective...
05
May
Results from a Pivotal Phase 3, DB, R, Placebo-controlled, Multicenter Trial of SP-102, a Novel Dexamethasone Injectable Formulation, for the Treatment of Patients with Lumbosacral Radiculopathy (Sciatica)
SP-102 (SEMDEXATM)...
